Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk

Katrin D. Mayer-Barber (), Bruno B. Andrade, Sandra D. Oland, Eduardo P. Amaral, Daniel L. Barber, Jacqueline Gonzales, Steven C. Derrick, Ruiru Shi, Nathella Pavan Kumar, Wang Wei, Xing Yuan, Guolong Zhang, Ying Cai, Subash Babu, Marta Catalfamo, Andres M. Salazar, Laura E. Via, Clifton E. Barry and Alan Sher
Additional contact information
Katrin D. Mayer-Barber: Immunobiology Section, Laboratory of Parasitic Diseases (LPD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
Bruno B. Andrade: Immunobiology Section, Laboratory of Parasitic Diseases (LPD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
Sandra D. Oland: Immunobiology Section, Laboratory of Parasitic Diseases (LPD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
Eduardo P. Amaral: Immunobiology Section, Laboratory of Parasitic Diseases (LPD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
Daniel L. Barber: T Lymphocyte Biology Unit, LPD, NIAID, NIH, Bethesda, Maryland 20892, USA
Jacqueline Gonzales: Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, NIAID, NIH, Bethesda, Maryland 20892, USA
Steven C. Derrick: Center for Biologics Evaluation and Research, Food and Drug Administration
Ruiru Shi: Henan Chest Hospital
Nathella Pavan Kumar: NIH, International Center for Excellence in Research, 600 031 Chennai, India
Wang Wei: Henan Chest Hospital
Xing Yuan: Henan Chest Hospital
Guolong Zhang: Sino-US International Research Center for Tuberculosis, and Henan Public Health Center
Ying Cai: Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, NIAID, NIH, Bethesda, Maryland 20892, USA
Subash Babu: NIH, International Center for Excellence in Research, 600 031 Chennai, India
Marta Catalfamo: Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland 20892, USA
Andres M. Salazar: Oncovir Inc.
Laura E. Via: Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, NIAID, NIH, Bethesda, Maryland 20892, USA
Clifton E. Barry: Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, NIAID, NIH, Bethesda, Maryland 20892, USA
Alan Sher: Immunobiology Section, Laboratory of Parasitic Diseases (LPD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Nature, 2014, vol. 511, issue 7507, 99-103

Abstract: Active tuberculosis has been linked to excessive type I interferon induction whereas interleukin-1 may have protective effects; here it is shown that interleukin-1 enhances the production of prostaglandin E2, which helps contain the pathogen while also suppressing detrimental type I interferon.

Date: 2014
References: Add references at CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://www.nature.com/articles/nature13489 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:511:y:2014:i:7507:d:10.1038_nature13489

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature13489

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().